Summary of Clinical Trials and AI Integration Industry Overview - The focus is on the clinical trials industry, which is facing challenges related to cost and efficiency, with a growing interest in integrating artificial intelligence (AI) to improve processes [1][8][9]. Key Points and Arguments Challenges in Clinical Trials - Clinical trials are costly and inefficient, with costs exceeding $2.5 billion for drug development [4]. - A study found that 54% of phase 3 trials fail, primarily due to insufficient efficacy (57%) and safety concerns (17%) [3]. - Recruitment issues are significant, with only 31% of UK trials meeting enrollment targets [4]. - From 2012 to 2022, R&D spending increased by 44%, yet the number of novel drug approvals remained flat, leading to higher average drug development costs [5]. - As of 2024, it is estimated that up to 80% of clinical trials exceed their forecasted timelines [5]. Potential of AI in Clinical Trials - AI is believed to have the potential to enhance various stages of clinical trials, including trial design, site selection, recruitment, monitoring, and analysis [9][10]. - AI can analyze real-world data (RWD) to improve trial design by refining patient eligibility criteria and optimizing endpoints [12]. - In site selection, AI can predict enrollment numbers and identify optimal trial locations, thus reducing costs and improving speed [14]. - For recruitment, AI can create comprehensive patient profiles from diverse data sources, improving eligibility matching and targeting underrepresented populations [16]. - AI can enhance monitoring by tracking site performance metrics in real-time, allowing for early identification of operational risks [18]. - In the analysis phase, AI can accelerate data cleaning and identify treatment effects that traditional methods may miss [20]. Companies Utilizing AI in Clinical Trials - A variety of companies are integrating AI into clinical trials, categorized into three groups: 1. **Full-fledged CROs**: Companies like IQVIA, Icon, and Fortrea are developing AI tools to enhance their internal trial processes [24]. 2. **Health-tech Companies**: Firms such as Medidata, ConcertAI, and Flatiron Health offer software platforms that utilize AI for various trial stages [24]. 3. **Diagnostics Companies**: Tempus and Caris Life Science focus on in-house sequencing and real-time patient matching [24]. Data and Partnerships - High-quality data is crucial for building effective AI models, with companies emphasizing the size and quality of their datasets [30][31]. - Partnerships are essential for enhancing datasets and improving AI models, with companies collaborating to combine resources and expertise [37][39]. Other Important Insights - The clinical trial industry is in the early stages of AI integration, with significant potential for transformation but also challenges due to regulatory complexities [39][40]. - The need for innovation in clinical trials is critical, whether through AI or other means, to address rising costs and operational inefficiencies [40]. This summary encapsulates the current state of the clinical trials industry, the challenges it faces, the potential role of AI, and the companies leading the charge in this transformation.

Group 1 - The company announced the acquisition of a total of 29,400 shares of Nebius for approximately $2.2 million on August 12, 2025 [1] - The company purchased 14,400 shares of Tempus for about $900,000 on August 12, 2025 [1] - Following the acquisition of Robinhood shares, the company further acquired 6,540 shares of Robinhood for approximately $800,000 on August 12, 2025 [1] Group 2 - The company sold 4,580 shares of Coinbase for approximately $1.5 million on August 12, 2025 [1] - The company also sold 63,200 shares of Innodata for about $2.6 million on August 12, 2025 [1]

Summary of Key Points Core Viewpoint - The company has made several strategic investments and divestments in various tech companies, indicating an active approach to portfolio management and potential growth opportunities in the tech sector [1]. Investment Activities - The company purchased a total of 29,400 shares of Nebius for approximately $2.2 million, excluding transaction costs [1]. - The company acquired 14,400 shares of Tempus for about $0.9 million, excluding transaction costs [1]. - Following its previous investment in Robinhood, the company further bought 6,540 shares of Robinhood for around $0.8 million, excluding transaction costs [1]. Divestment Activities - The company sold 4,580 shares of Coinbase for approximately $1.5 million, excluding transaction costs [1]. - The company divested 63,200 shares of Innodata for about $2.6 million, excluding transaction costs [1].

Summary of Key Points Core Viewpoint - The company has made several strategic transactions in the public market, involving both acquisitions and sales of shares in various companies, indicating an active investment strategy aimed at portfolio diversification and potential profit realization. Group 1: Acquisitions - On August 12, 2025, the company purchased a total of 29,400 shares of Nebius for approximately $2.2 million (excluding transaction costs) [1] - On August 12, 2025, the company acquired 14,400 shares of Tempus for about $900,000 (excluding transaction costs) [1] - On August 12, 2025, the company further acquired 6,540 shares of Robinhood for approximately $800,000 (excluding transaction costs) [1] Group 2: Sales - On August 12, 2025, the company sold 4,580 shares of Coinbase for about $1.5 million (excluding transaction costs) [1] - On August 12, 2025, the company sold 63,200 shares of Innodata for approximately $2.6 million (excluding transaction costs) [1]

Financial Data and Key Metrics Changes - Total company revenue for Q2 2025 was $17.2 million, a 24% decrease from $22.6 million in the same period last year [20] - Biopharma revenue was $11.1 million, down 16% from $13.2 million year-over-year, primarily due to project delays and a decline from Moderna [21] - Gross margin decreased to 27.6% from 35.6% year-over-year, impacted by lower revenue and unreimbursed clinical test costs [22] - Net loss for Q2 was $20.1 million compared to $12.8 million in the prior year [23] Business Line Data and Key Metrics Changes - Clinical revenue recognized was $500,000 from NEXT Dx and NEXT Personal Molecular tests, up from $100,000 year-over-year [21] - The number of clinical tests delivered in Q2 was 3,478, a 59% increase from Q1 and over 575% growth from the previous year [13] - The company expects to grow its MRD segment by 300% to 400% this year, with significant revenue contributions anticipated in Q4 [11] Market Data and Key Metrics Changes - The minimal residual disease (MRD) market is projected to exceed $20 billion annually, with Personalis positioned to capture a significant share [7] - The company is actively pursuing Medicare coverage for two indications by the end of the year, which is expected to unlock a significant revenue stream [12] Company Strategy and Development Direction - The company is focused on accelerating clinical adoption through partnerships, particularly with Tempus, and expanding its base of ordering physicians [6][13] - A three-point action plan is in place to pursue the high end of the revised revenue guidance, focusing on biopharma pipeline conversion, clinical momentum, and reimbursement advancements [10] - The company aims to achieve Medicare reimbursement for two indications this year, which is seen as a pivotal catalyst for growth [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged industry-wide headwinds in biopharma R&D spending and political changes affecting customer projects, leading to revenue shifts [9] - The company remains confident in its MRD technology's demand and is actively managing its near-term challenges [10] - Management expressed optimism about the clinical adoption of its technology and the potential for significant revenue growth post-reimbursement [18] Other Important Information - The company ended Q2 with $173.2 million in cash and short-term investments, with no debt other than minor equipment loans [24] - Cash usage for operations and capital equipment additions in Q2 was $13.2 million, with an expected total cash usage of approximately $75 million for the full year [25] Q&A Session Summary Question: Rationale for lowering clinical revenue guidance - Management explained that the guidance was narrowed due to the timing of reimbursement and expected to achieve reimbursement for one indication in Q3 and another in Q4 [30][31] Question: Early use cases and physician engagement - Management highlighted that the technology is being used effectively in breast cancer, lung cancer, and immunotherapy monitoring, with high retention rates among physicians [34][36] Question: Cash flow and future funding needs - Management confirmed that the current cash position is sufficient to reach cash flow breakeven without needing to raise additional funds [40][41] Question: Impact of policy headwinds on biopharma customers - Management noted that project delays are expected to convert to revenue in the next two to four quarters, with strong growth in the MRD offering [72] Question: Differentiation of NextPersonal in the competitive landscape - Management emphasized the strength of their clinical evidence and ongoing investments in evidence development to support reimbursement applications [75] Question: Conversations at ASCO and future implementation - Management reported positive feedback from ASCO, reinforcing the predictive capabilities of their tests and plans to expand reimbursement applications [84][86]

Financial Data and Key Metrics Changes - The company ended the quarter with a strong cash balance of $533 million, reflecting effective expense management and cash inflows from partnerships and tax credits [42][43] - Expected cash burn in 2026 is projected to be 35% less than the previous year, demonstrating a commitment to operational efficiency [43] Business Line Data and Key Metrics Changes - The company is advancing a pipeline of internal programs in oncology and rare diseases, alongside collaborations with partners like Roche, Sanofi, Bayer, and Merck KGA [7][39] - The ClinTech platform is being deployed across all programs, enhancing patient stratification and trial execution, with projections for 50% faster enrollment at high-quality sites [6][7] Market Data and Key Metrics Changes - The company is leveraging proprietary datasets and AI to enhance drug discovery and development, with significant advancements in partnerships and internal programs [11][39] - The partnership with Sanofi achieved its fourth milestone, indicating progress in challenging targets within immunology and oncology [39] Company Strategy and Development Direction - The focus is on building a comprehensive drug discovery platform, Recursion OS 2.0, integrating various data sources and technologies to improve the efficiency and success rate of drug development [46][47] - The company aims to bring unique biological insights and new targets to the clinic faster and at lower costs, emphasizing the importance of high-quality programs [8][47] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting a catalyst-packed calendar with multiple readouts expected in the coming quarters [48] - The company is committed to maintaining a high bar for quality while exploring innovative approaches to drug discovery and development [46][47] Other Important Information - The company is actively working on a virtual cell model to predict cellular responses to various interventions, which could significantly enhance drug discovery efforts [78][80] - The integration of AI and multiomic data is central to the company's strategy, allowing for more precise patient targeting and drug design [16][57] Q&A Session Summary Question: Is Bolts two the initiative with a major partner on foundational protein structure modeling? - Yes, Bolts two is the partnership mentioned earlier, aimed at enhancing protein structure modeling [49] Question: Why open source versus keeping it internal? - The company believes in commoditizing certain technologies while retaining proprietary tools that provide a competitive advantage [50] Question: For the CDK7 combo expansion cohort in ovarian cancer, what standard of care are you allowing in the trial? - The standard of care will include single-agent chemotherapy plus Bevacizumab, with a median PFS of about 6.7 months [52][53] Question: Do you expect the data from multiomic profiling for RBM 39 to dictate future patient enrollment? - Yes, the data will help select patients for future studies, focusing on those with specific biomarkers [55][57] Question: What is the differentiation of RBM 39 compared to other CDK targeting assets? - RBM 39 is not a kinase and offers selectivity advantages over similar targets like CDK 12 and CDK 13 [61] Question: What visibility do you have on the potential $100 million in milestones by 2026? - The guidance is based on existing partnerships and programs, with probability-weighted estimates for milestone achievements [70][71] Question: How does the company plan to achieve its cash runway guidance through Q4 2027? - The company is focused on cash flows, managing expenses efficiently, and executing existing partnerships to ensure a sustainable cash runway [72][75] Question: What ambitious initiatives are being planned to reflect the next level of thinking? - The company is investing in large-scale compute initiatives and developing a virtual cell model to enhance drug discovery capabilities [78][80]

Core Viewpoint - Baillie Gifford, a legendary asset management company, has successfully identified and invested in disruptive growth stocks like Tesla, Amazon, and SpaceX, positioning itself as a leader in long-term growth investment [1][2]. Group 1: Company Overview - Baillie Gifford was established in 1908 and is headquartered in Edinburgh, known for its long-term investment strategies [1]. - The flagship product, Scottish Mortgage Investment Trust (SMT), is regarded as a benchmark for ultra-long-term investments [2]. - SMT currently manages approximately £13.3 billion in assets, with a net return of about 13% over the past year, a cumulative loss of around 30% over the last three years, and an annualized return of about 12% over the past decade [2]. Group 2: Investment Strategy and Portfolio - SMT's recent key holdings include publicly traded companies such as MercadoLibre (5.9%), Amazon (5.6%), and Meta (4.7%), as well as private companies like SpaceX (valued at approximately £1.071 billion) and ByteDance (approximately £566 million) [3]. - The current management team, led by Tom Slater and Lawrence Burns, emphasizes resilience as a core virtue for long-term success in unpredictable environments [4][22]. Group 3: Market Conditions and Company Performance - The past year has seen significant challenges, including high interest rates and geopolitical volatility, yet many invested companies have shown impressive operational performance [7]. - Companies have adapted by reducing expansion rates and refocusing on core strengths, leading to improved profit margins and accelerated free cash flow [10][11]. Group 4: AI and Technological Advancements - The rise of generative AI has had a profound impact, particularly in software engineering, leading to significant productivity gains [12][13]. - Companies like Meta and Spotify have successfully integrated AI into their operations, enhancing efficiency and revenue growth [19][20]. Group 5: Global Investment Perspective - SMT has leveraged its global investment mandate, focusing on companies like MercadoLibre, which has shown strong performance despite macroeconomic challenges in Latin America [36]. - The investment in Nubank, a leading independent digital bank outside China, highlights the potential for growth in emerging markets [39]. Group 6: Future Outlook and Emerging Opportunities - Baillie Gifford is actively seeking the next generation of winners, with investments in companies like SpaceX and Aurora Innovation, which are poised to reshape their respective industries [47][50]. - The company remains committed to identifying transformative opportunities and supporting innovative firms that can deliver substantial long-term returns [57].

Group 1 - The report highlights that all six sub-sectors of the pharmaceutical index recorded positive returns, indicating strong performance in the market [1][10]. - AI medical companies in the US have shown robust performance, with Hims&Hers Health reporting a first-quarter revenue of $586 million, a significant year-on-year increase of 111% [7][8]. - The market for medical large models is experiencing rapid growth, with an average annual compound growth rate exceeding 100% from 2019 to 2023, and is expected to reach 11.16 billion by 2028 [2][8]. Group 2 - The penetration rate of medical large models is currently low, with projections indicating it could exceed 40% by 2030, up from approximately 1% in 2020 [2][8]. - The report notes that the current market size of medical large models is close to 2 billion, with expectations of a high average growth rate of 140% during the industry explosion period [8]. - The report identifies a lack of clear safety, efficacy validation, and regulatory frameworks as significant limiting factors for the commercialization of medical large models [9].

策略研究 | 证券研究报告 — 总量周报 2025 年 5 月 11 日 策略周报 政策落地，待新催化 政策预期阶段性落地，市场信心得到有力支撑，科技主线等待回归，配置上 "以我为主"，关注内需、科技自主相关板块。 中银国际证券股份有限公司 具备证券投资咨询业务资格 策略研究 证券分析师：王君 (8610)66229061 jun.wang@bocichina.com 证券投资咨询业务证书编号：S1300519060003 证券分析师：徐沛东 (8621)20328702 peidong.xu@bocichina.com 证券投资咨询业务证书编号：S1300518020001 证券分析师：郭晓希 (8610)66229019 xiaoxi.guo@bocichina.com 证券投资咨询业务证书编号：S1300521110001 证券分析师：徐亚 (8621)20328506 ya.xu@bocichina.com 证券投资咨询业务证书编号：S1300521070003 证券分析师：高天然 tianran.gao@bocichina.com 证券投资咨询业务证书编号：S1300522100001 国新办发布会 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that are likely to benefit from the overseas AI healthcare performance, specifically mentioning companies like RunDa Medical and YiMaiTong as having strong potential for AI-driven revenue growth [5][10]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring companies such as RunDa Medical, YiMaiTong, and others that are expected to achieve rapid AI performance growth [10]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top five performing stocks during this period included Changshan Pharmaceutical (up 23.59%), Xiangxue Pharmaceutical (up 19.64%), and others [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei for AI applications across various healthcare settings, providing digital solutions to over 80 hospitals by the end of 2024 [12][13]. - YiMaiTong, a leading online professional physician platform, has seen its registered physician count grow from 228,000 in 2018 to 867,000 in 2024, with a compound annual growth rate (CAGR) of 24.9% [17][20]. The company’s revenue increased from 83.46 million yuan to 558.46 million yuan from 2018 to 2024, reflecting a CAGR of 37.3% [20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and others, indicating a focus on innovative drugs and companies with emerging performance [5]. 5. Market Valuation and Trading Volume - As of May 9, 2025, the overall valuation of the Shenwan Pharmaceutical sector was 32.3, with a slight increase from the previous week [38]. The total trading volume for the sector reached 287.2 billion yuan, accounting for 5.3% of the total A-share trading volume [40].